Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Tuberculosis, Pulmonary
    Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group
    Sponsors:   Andrew Dinardo;   Celgene Corporation
    Not yet recruiting

  • Condition:   Perforated Appendicitis
    Interventions:   Drug: antibiotic rinse with suction;   Procedure: suction only
    Sponsor:   Prisma Health-Upstate
    Recruiting

  • Conditions:   Antibiotic Resistant Infection;   Nosocomial Infection;   Pathogen Transmission;   Nutrition Disorders;   Critical Illness;   Sepsis
    Interventions:   Drug: Inulin Oral Suspension;   Drug: Placebo Oral Suspension;   Drug: Broad-spectrum antibiotics
    Sponsor:   Columbia University
    Not yet recruiting

  • Conditions:   Severe Clostridium Difficile Infection;   Severe-Complicated/Fulminant Clostridium Difficile Infection
    Interventions:   Drug: Penn Microbiome Therapy - 001;   Drug: Penn Microbiome Therapy - 002;   Drug: Penn Microbiome Therapy - 003;   Drug: Antibiotics
    Sponsor:   University of Pennsylvania
    Not yet recruiting

  • Condition:   Chronic Rhinosinusitis (Diagnosis)
    Intervention:   Drug: Topical Antibiotic Nasal Saline Irrigation
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Clostridium Difficile Infection;   C.Difficile Diarrhea;   CDI
    Interventions:   Drug: Low Dose FMT Capsule DE;   Drug: Single Dose FMT Capsule DE;   Drug: Placebo oral capsule
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Condition:   Prolonged Air Leak
    Interventions:   Other: Oral Antibiotics-Close Monitoring;   Other: Standard of Care
    Sponsor:   Mayo Clinic
    Not yet recruiting

  • Conditions:   Cystitis;   Cystitis;Puerperium;   Pyelonephritis
    Interventions:   Drug: Antibiotic;   Other: Standard Prenatal Care
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Conditions:   Antimicrobial Stewardship;   Acute Bronchitis;   Upper Respiratory Infection
    Intervention:   Behavioral: Antibiotic Stewardship
    Sponsors:   Los Angeles Biomedical Research Institute;   Los Angeles County Department of Public Health;   University of California, Los Angeles
    Recruiting

  • Condition:   Occlusion
    Interventions:   Device: Clear Bactiseal 'large' catheter (EVD);   Device: Orange Bactiseal 'small' catheter (EVD)
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Condition:   Malignant Neoplasms of Independent (Primary) Multiple Sites
    Interventions:   Other: Tongue Assessment;   Other: Stool Sample;   Behavioral: Questionnaires;   Device: Holter Monitor;   Other: Yogurt
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting

  • Conditions:   Obesity, Childhood;   Antibiotic Side Effect
    Intervention:  
    Sponsors:   Children's Hospital of Philadelphia;   University of Minnesota - Clinical and Translational Science Institute;   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Appendicitis
    Interventions:   Other: Non-operative treatment;   Procedure: Appendectomy
    Sponsors:   Children's Mercy Hospital Kansas City;   Provincial Health Services Authority;   Alberta Children's Hospital;   Children's Hospital of Western Ontario;   St. Justine's Hospital;   Children's Hospital of Winnipeg;   Le Bonheur Children's Hospital;   Karolinska University Hospital;   Hospital for Children and Adolescents, Finland;   University of Southampton;   UCL Institute of Child Health;   KK Women's and Children's Hospital;   Uppsala University Children's Hospital
    Recruiting

  • Conditions:   Osteoarthritis;   Hip Infection;   Prosthetic Joint Infection;   Complications; Arthroplasty, Infection or Inflammation;   Complications; Arthroplasty
    Interventions:   Procedure: Implantation of a static, non-articulating cement spacer.;   Procedure: Implantation of an articulating spacer.
    Sponsors:   Rush University Medical Center;   Thomas Jefferson University;   Central DuPage Hospital
    Recruiting

  • Conditions:   Obesity;   Induction of Labor Affected Fetus / Newborn
    Interventions:   Drug: Cefazolin;   Drug: Placebo;   Drug: Azithromycin
    Sponsor:   University of Oklahoma
    Recruiting

  • Conditions:   Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture);   Rupture of Membranes; Premature;   Rupture of Membranes; Premature, Affecting Fetus;   Preterm Birth;   Preterm PROM (Pregnancy);   Preterm Labor
    Intervention:   Drug: Antibiotics, oral Azithromycin and oral Amoxicillin
    Sponsor:   Woman's
    Recruiting

  • Conditions:   Inflammation at Mini-screw Insertion Site;   Mobility, Mini-screw
    Interventions:   Drug: Amoxicillin;   Drug: Placebo oral capsule
    Sponsor:   St. Louis University
    Recruiting

  • Conditions:   Premalignant Vulvar Lesion;   Benign Vulvar Lesion
    Intervention:   Drug: Cefazolin
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Fractures, Open
    Interventions:   Drug: Tobramycin;   Other: Placebo: normal saline
    Sponsor:   University of Virginia
    Recruiting

  • Conditions:   Clostridium Difficile Infection;   Clostridium Difficile Infection Recurrence
    Interventions:   Drug: Oral Vancomycin;   Other: placebo
    Sponsor:   University of South Florida
    Not yet recruiting

  • Condition:   Open Fracture
    Intervention:   Drug: Vancomycin
    Sponsors:   The University of Texas Health Science Center at San Antonio;   United States Army Institute of Surgical Research;   San Antonio Military Medical Center
    Not yet recruiting

  • Conditions:   HIV Infections;   Tuberculosis
    Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC)
    Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Total Knee Replacement
    Interventions:   Drug: hand mixed vancomycin;   Drug: hand mixed tobramycin;   Device: pre-mixed tobramycin
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Carpal Tunnel Syndrome
    Interventions:   Drug: Vancomycin;   Drug: Cefazolin;   Drug: Saline Solution
    Sponsor:   WellSpan Health
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Procedure: Lymph node template;   Procedure: Transverse versus vertical closure;   Drug: antibiotic prophylaxis
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Osteoarthritis;   Knee Infection;   Prosthetic Joint Infection;   Complications; Arthroplasty, Infection or Inflammation;   Complications; Arthroplasty
    Interventions:   Procedure: Static Spacer;   Procedure: Articulating Spacer
    Sponsors:   Rush University Medical Center;   Central DuPage Hospital;   Joint Implant Surgeons, Inc.;   Thomas Jefferson University
    Recruiting

  • Condition:   Surgical Site Infection
    Interventions:   Drug: topical irrigation with the antibiotic bacitracin;   Drug: topical irrigation with sterile normal saline (NS);   Drug: intravenous (IV) prophylactic antibiotic
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Condition:   Clostridium Difficile Infection (CDI)
    Interventions:   Drug: Fidaxomicin;   Drug: Vancomycin
    Sponsors:   University of Michigan;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Drug: Antibiotics and Pembrolizumab
    Sponsor:   NYU Langone Health
    Not yet recruiting

  • Condition:   Prosthesis-Related Infections
    Intervention:   Other: Oral Antibiotics
    Sponsor:   Rush University Medical Center
    Recruiting

  • Condition:   Ulcerative Colitis (UC)
    Interventions:   Other: Ulcerative Colitis Diet;   Drug: Antibiotic cocktail
    Sponsor:   Prof. Arie Levine
    Recruiting

  • Condition:   Chronic Sinus Infection
    Intervention:   Drug: Amoxi Clavulanate
    Sponsor:   Montefiore Medical Center
    Recruiting

  • Condition:   Lower Respiratory Tract Infection
    Interventions:   Drug: Azithromycin;   Other: Placebo;   Device: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Antibiotic Resistant Infection
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Facial Defect
    Intervention:   Drug: cephalexin
    Sponsor:   University of Michigan
    Recruiting

  • Condition:   Chronic Rhinosinusitis
    Interventions:   Drug: oral levofloxacin;   Drug: nebulized levofloxacin
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Perforated Appendicitis;   Postoperative Infection
    Intervention:   Drug: piperacillin-tazobactam
    Sponsor:   Phoenix Children's Hospital
    Recruiting

  • Conditions:   Obstetric Complication;   Postpartum Hemorrhage;   Postpartum Endometritis
    Interventions:   Drug: CeFAZolin 1000 MG;   Drug: Clindamycin 900 MG in 6 ML Injection
    Sponsor:   Cedars-Sinai Medical Center
    Recruiting

  • Condition:   Abdominal Abscess
    Interventions:   Drug: Gentamicin Sulfate Inj 20mg/2ml vial for injection;   Drug: Clindamycin phosphate 6 mg/1ml for injection;   Other: Placebo
    Sponsor:   Paolo Goffredo
    Recruiting

  • Conditions:   Intestinal Microbiome;   Febrile Neutropenia
    Interventions:   Drug: Piperacillin-tazobactam;   Drug: cefepime
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Supracondylar Humerus Fracture;   Post Operative Wound Infection
    Interventions:   Drug: Cefazolin;   Drug: Clindamycin;   Drug: Saline
    Sponsors:   Sumit Gupta;   University of Missouri-Columbia
    Recruiting

  • Conditions:   Urolithiasis;   UTI
    Interventions:   Drug: Ciprofloxacin;   Drug: trimethoprim/sulfamethoxazole;   Drug: No Intervention
    Sponsors:   University of California, San Diego;   Genesis HealthCare
    Recruiting

  • Condition:   Cholangitis
    Interventions:   Drug: Ceftriaxone;   Drug: Levofloxacin
    Sponsor:   University of Southern California
    Recruiting

  • Conditions:   Nephrolithiasis;   Urinary Tract Infection (UTI);   Sepsis
    Interventions:   Drug: Nitrofurantoin 100 MG, 7d;   Drug: Gentamicin, 5mg/kg;   Drug: Ampicillin 2g;   Drug: Nitrofurantoin 100 mg, 48 hrs;   Drug: Gentamicin, 80 mg, 7d;   Drug: Gentamicin, 80 mg, 48hr
    Sponsor:   University of California, San Diego
    Recruiting

  • Condition:   Ulcerative Colitis
    Interventions:   Biological: Fecal Microbiota Transplantation (FMT), OpenBiome;   Other: pretreatment antibiotics
    Sponsor:   Najwa Elnachef
    Recruiting

  • Condition:   Salivary Duct
    Intervention:   Drug: Postoperative Oral Antibiotics (Clindamycin or Augmentin)
    Sponsors:   Our Lady of the Lake Hospital;   Louisiana State University Health Sciences Center in New Orleans
    Recruiting

  • Condition:   Urinary Tract Infection (UTI)
    Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting

  • Condition:   Catheter-related Infections
    Interventions:   Drug: Mino-Lok;   Drug: Antibiotic lock
    Sponsor:   Leonard-Meron Biosciences, Inc.
    Recruiting

  • Condition:   Antibiotic Stewardship
    Intervention:   Other: Opt-Out Protocol
    Sponsor:   Duke University
    Recruiting

  • Condition:   Pulmonary Cystic Fibrosis
    Intervention:   Drug: Standard of care IV antibiotic(s)
    Sponsors:   Chris Goss;   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center;   Medical University of South Carolina;   University of Washington
    Recruiting

  • Condition:   Bacteremia
    Interventions:   Drug: DSTA4637S;   Drug: Placebo;   Drug: SOC
    Sponsor:   Genentech, Inc.
    Recruiting

  • Conditions:   Overactive Bladder;   Urinary Tract Infections
    Interventions:   Procedure: Periprocedural Antibiotics;   Drug: Extended Antibiotics;   Procedure: Injection of OnabotulinumtoxinA (BTX-A)
    Sponsors:   Vanderbilt University Medical Center;   The Allergan Foundation;   Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
    Recruiting

  • Condition:   Ventral Hernia Repair
    Interventions:   Drug: Gemcitabine/ clindamycin;   Drug: Normal saline
    Sponsors:   Prisma Health-Upstate;   Washington University School of Medicine;   The Cleveland Clinic;   Penn State University;   Oregon Health and Science University;   Ohio State University;   New Hanover Regional Medical Center;   University of Pennsylvania
    Recruiting

  • Condition:   Bacterial Pneumonia
    Interventions:   Drug: Cefiderocol;   Drug: Standard of Care Antibiotic
    Sponsor:   Shionogi
    Recruiting

  • Conditions:   Arthropathy of Knee;   Antibiotic Prophylaxis
    Intervention:   Drug: Cefazolin
    Sponsors:   Duke University;   American Association of Hip and Knee Society
    Recruiting

  • Conditions:   Infection;   Bone Neoplasms
    Interventions:   Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;   Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
    Sponsors:   McMaster University;   Orthopedic Research and Education Foundation;   The Physicians' Services Incorporated Foundation;   Canadian Cancer Society Research Institute (CCSRI);   Canadian Institutes of Health Research (CIHR)
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Placebo for antibiotic;   Drug: Vancomycin pretreatment;   Drug: Nivolumab;   Drug: Matching Placebo for SER-401;   Drug: SER-401
    Sponsors:   Parker Institute for Cancer Immunotherapy;   Seres Therapeutics, Inc.
    Recruiting

  • Condition:   Rabies Human
    Interventions:   Biological: Rabies Vaccine;   Drug: Metronidazole;   Drug: Vancomycin;   Drug: Neomycin Sulfate
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Antibiotic Side Effect;   Eyelid; Wound;   Eyelid Diseases;   Surgical Wound Infection;   Surgical Wound, Recent;   Surgical Incision;   Skin Cancer Face;   Antibiotic Allergy;   Surgical Site Infection
    Interventions:   Drug: Topical Anti-Infective Product;   Drug: Topical Ointment
    Sponsor:   University of California, San Francisco
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Chlorhexidine irrigation;   Drug: triple antibiotic irrigation
    Sponsor:   Vanderbilt University Medical Center
    Recruiting

  • Conditions:   Sick Sinus Syndrome;   Complete Heart Block;   Syncope;   Chronic Systolic Heart Failure
    Interventions:   Drug: polymixin/bacitracin;   Drug: cephalexin, or levofloxacin, or clindamycin;   Drug: Saline
    Sponsors:   Vanderbilt University Medical Center;   Thomas Jefferson University;   The Cooper Health System;   Valley Health System;   Medtronic
    Recruiting

  • Condition:   Anthrax
    Interventions:   Drug: Ciprofloxacin 500Mg Tablet;   Drug: Doxycycline 100Mg Tablet;   Biological: AV7909
    Sponsors:   Emergent Product Development Gaithersburg, Inc.;   Biomedical Advanced Research and Development Authority
    Recruiting

  • Condition:   Drug-drug Interaction
    Intervention:   Drug: Intravenous Rifampin
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Idiopathic Infantile Hypercalcaemia - Severe Form;   Genetic Disease;   Hypercalcemia, Idiopathic, of Infancy;   Hypercalciuric Hypercalcemia;   Idiopathic Infantile Hypercalcemia - Mild Form;   Hypercalciuria
    Intervention:   Drug: Rifampin
    Sponsors:   Children's Hospital of Philadelphia;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Sinusitis;   Respiratory Tract Infections
    Interventions:   Drug: Amoxicillin-clavulanate;   Drug: Placebo
    Sponsors:   University of Pittsburgh;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Healthy Participants
    Interventions:   Drug: BMS-986256;   Drug: Mycophenolate Mofetil
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Psychological Stress;   Hypertension, Renal
    Interventions:   Drug: mycophenolate mofetil (MMF);   Drug: Placebo
    Sponsor:   Augusta University
    Recruiting

  • Condition:   Spinal Cord Injury
    Interventions:   Drug: D-Cycloserine;   Drug: Placebo;   Other: Training;   Other: Stimulation;   Other: Placebo Stimulation
    Sponsors:   University of Miami;   The Craig H. Neilsen Foundation
    Recruiting

  • Conditions:   Kidney Transplant;   Renal Transplant Recipients
    Interventions:   Biological: DCreg: 0.5 million cells/kg+SOC;   Biological: DCreg: 1.2 million cells/kg+SOC;   Biological: DCreg:2.5 to 5.0 million cells/kg+SOC
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   University of Pittsburgh
    Recruiting

  • Conditions:   Kidney Transplantation;   Renal Transplantation;   Renal Transplant Recipient
    Interventions:   Biological: Donor-derived Mesenchymal Stromal Cells;   Drug: alemtuzumab;   Drug: belatacept;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Drug: mycophenolate acid;   Drug: prednisone
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting

  • Condition:   Gout Chronic
    Interventions:   Drug: Pegloticase 8 MG/ML [Krystexxa];   Drug: MMF;   Drug: Placebo
    Sponsors:   University of Alabama at Birmingham;   University of Michigan
    Recruiting

  • Conditions:   Kidney Transplant Rejection;   Gastrointestinal Disorder, Functional
    Interventions:   Drug: Everolimus;   Drug: Mycophenolic Acid
    Sponsors:   Washington University School of Medicine;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Low Back Pain;   Pain
    Interventions:   Drug: D-cycloserine;   Drug: Placebo
    Sponsors:   Northwestern University;   United States Department of Defense
    Recruiting

  • Conditions:   Interstitial Lung Disease;   ILD;   Systemic Sclerosis;   Scleroderma
    Interventions:   Drug: Bortezomib;   Drug: Placebo;   Drug: Mycophenolate mofetil
    Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Recurrent Acute Myeloid Leukemia, Adult;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: mycophenolate mofetil;   Biological: Sargramostim;   Biological: Filgrastim
    Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
    Recruiting

  • Condition:   SCI
    Interventions:   Behavioral: hypoxia;   Behavioral: sham hypoxia;   Drug: D-cycloserine;   Drug: sham-NMDA agonist;   Behavioral: exercise training
    Sponsor:   VA Office of Research and Development
    Not yet recruiting

  • Condition:   Gulf War Illness
    Interventions:   Drug: D-cycloserine;   Drug: Placebos
    Sponsor:   Boston University Charles River Campus
    Recruiting

  • Condition:   Type 1 Diabetes Mellitus
    Intervention:   Drug: Myfortic
    Sponsor:   Rodolfo Alejandro
    Recruiting

  • Condition:   Healthy Volunteers
    Interventions:   Drug: Vemlidy (tenofivir alafenamide);   Drug: Priftin (rifapentine);   Drug: Isoniazid;   Dietary Supplement: Pyridoxine
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Condition:   PTSD
    Interventions:   Behavioral: CBT + ImRs;   Behavioral: CBT + I.E.;   Drug: D-Cycloserine;   Drug: Placebo;   Drug: Study Pill
    Sponsors:   Boston University Charles River Campus;   James S McDonnell Foundation
    Recruiting

  • Conditions:   Donor;   Non-Malignant Neoplasm
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Lapine T-Lymphocyte Immune Globulin;   Radiation: Total-Body Irradiation;   Procedure: Hematopoietic Cell Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Healthy Volunteers
    Interventions:   Drug: rifapentene (RPT);   Drug: darunavir/cobicistat (DRV/c);   Drug: Isoniazid (INH);   Dietary Supplement: Pyridoxine
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Graft Versus Host Disease;   Hematologic Neoplasms
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hyperkalemia;   Kidney Transplant
    Intervention:   Drug: Patiromer
    Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Lung Transplant Rejection;   Antibody-mediated Rejection
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: ATG;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone;   Drug: Prednisone
    Sponsors:   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Disorder;   Hemoglobinopathies;   Thalassemia;   Anemia, Sickle Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Rabbit anti-thymocyte globulin;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
    Sponsors:   City of Hope Medical Center;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Device: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   The V Foundation for Cancer Research;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Spinal Cord Injury
    Interventions:   Drug: Seromycin;   Device: STDP;   Other: Training;   Drug: Dextromethorphan;   Drug: Seromycin Placebo;   Drug: Dextromethorphan Placebo;   Device: Sham STDP
    Sponsors:   VA Office of Research and Development;   University of Miami
    Recruiting

  • Conditions:   Transplant; Failure, Kidney;   EBV
    Interventions:   Drug: belatacept;   Drug: Tacrolimus;   Drug: MPA
    Sponsors:   Lorenzo Gallon;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Allogeneic Lymphocytes;   Radiation: Total Nodal Irradiation
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Posttraumatic Stress Disorder
    Interventions:   Drug: DCS;   Other: Placebo
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Gemcitabine Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Conditions:   Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   University of California, Davis;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine;   Drug: Cytoxan;   Radiation: Total Body Irradiation;   Procedure: Allogeneic Blood or Marrow Transplant;   Procedure: Peripheral Blood Stem Cell Transplant;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurological Disorder;   Autoimmune Diseases
    Interventions:   Drug: Mycophenolate Mofetil;   Drug: Azathioprine
    Sponsors:   Duke University;   Beth Israel Deaconess Medical Center;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Idiopathic Pulmonary Fibrosis, Acute Fatal Form
    Interventions:   Drug: Autoantibody Reductive Therapy;   Drug: Treatment as Usual (TAU)
    Sponsors:   University of Alabama at Birmingham;   National Heart, Lung, and Blood Institute (NHLBI);   Brigham and Women's Hospital;   Temple University;   University of Pittsburgh
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Kidney Transplantation;   Immunosuppression
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus];   Drug: Mycophenolate Mofetil;   Drug: Mycophenolic Acid Oral Product;   Drug: Tacrolimus;   Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
    Sponsors:   Simon Tremblay, PharmD, PhD;   Veloxis Pharmaceuticals
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: anti-thymocyte globulin (rabbit);   Drug: Rituximab;   Radiation: Total Body Irradiation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Calcinosis Cutis
    Interventions:   Drug: Sodium Thiosulfate;   Other: Saline Solution
    Sponsor:   University of Central Florida
    Recruiting

  • Conditions:   Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
    Interventions:   Drug: Cisplatin;   Drug: Sodium thiosulfate;   Procedure: Cytoreductive surgery
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   Juvenile Dermatomyositis;   Dermatomyositis;   Idiopathic Inflammatory Myopathies
    Intervention:   Drug: Sodium Thiosulfate
    Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
    Recruiting

  • Conditions:   Gastric Adenocarcinoma;   Esophagogastric Junction;   Gastric Cancer
    Interventions:   Procedure: Surgery;   Drug: Cisplatin;   Drug: Mitomycin C;   Drug: Sodium Thiosulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia;   Donor
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Drug: Amoxicillin;   Drug: Amoxicillin-clavulanate;   Drug: Cefdinir;   Other: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Appendicitis
    Interventions:   Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin;   Procedure: Appendectomy
    Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Conditions:   Living-Donor Kidney Transplant;   Kidney Transplant Recipients
    Interventions:   Biological: lulizumab pegol;   Biological: antithymocyte globulin (rabbit);   Drug: methylprednisolone;   Biological: tocilizumab;   Drug: Prednisone;   Drug: everolimus;   Biological: belatacept;   Drug: mycophenolate mofetil;   Drug: mycophenolic acid
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Bristol-Myers Squibb;   Clinical Trials in Organ Transplantation
    Not yet recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Mycobacterium Avium Complex;   Nontuberculous Mycobacterium Infection
    Interventions:   Drug: Azithromycin;   Drug: Ethambutol;   Drug: Rifampin
    Sponsors:   Kevin Winthrop;   Patient-Centered Outcomes Research Institute;   National Jewish Health;   The University of Texas Health Science Center at Tyler;   University Health Network, Toronto;   New York University;   Medical University of South Carolina;   Mayo Clinic;   Georgetown University;   University of Chicago;   Louisiana State University Health Sciences Center in New Orleans;   University of California, San Diego;   Stanford University;   University of Kansas;   Vancouver Clinic;   University of California, San Francisco;   University of Washington;   Johns Hopkins University;   University of Miami;   Emory University;   University of Iowa;   University of North Carolina;   Yale University;   Temple University;   Loma Linda University;   Columbia University;   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Osteomyelitis;   Diabetes;   Amputation
    Interventions:   Drug: Rifampin;   Drug: Riboflavin Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting

  • Condition:   Latent Tuberculosis
    Interventions:   Drug: Rifapentine daily for 6 weeks;   Drug: Rifapentine and Isoniazid weekly for 12 weeks;   Drug: Rifampin and Isoniazid daily for 12 weeks;   Drug: Rifampin daily for 16 weeks
    Sponsors:   Centers for Disease Control and Prevention;   British Medical Research Council
    Recruiting

  • Conditions:   Scleroderma, Systemic;   Interstitial Lung Disease
    Interventions:   Drug: Pirfenidone (PFD);   Drug: Placebo (Plac);   Drug: Mycophenolate Mofetil (MMF)
    Sponsors:   Michael Roth;   University of Michigan;   Genentech, Inc.;   University of California, Los Angeles
    Recruiting

  • Condition:   Uveitis
    Interventions:   Biological: Adalimumab (ADA);   Drug: Conventional immunosuppression (CON)
    Sponsor:   JHSPH Center for Clinical Trials
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplasia;   Lymphoma
    Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
    Recruiting

  • Conditions:   Pediatric Heart Transplantation;   Immunosuppression;   Chronic Kidney Diseases;   Cardiac Allograft Vasculopathy;   Heart Transplant Failure and Rejection;   Post-transplant Lymphoproliferative Disorder;   Heart Transplant Infection
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsors:   Boston Children’s Hospital;   Stanford University;   United States Department of Defense
    Recruiting

  • Condition:   Heart Transplant
    Interventions:   Biological: tocilizumab;   Biological: Placebo;   Drug: Standard of Care Triple IS
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Age-Related Macular Degeneration
    Interventions:   Drug: ASP7317;   Other: Placebo;   Drug: tacrolimus;   Drug: mycophenolate mofetil (MMF)
    Sponsor:   Astellas Institute for Regenerative Medicine
    Recruiting

  • Condition:   Graft-versus-host Disease (GVHD)
    Interventions:   Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Kidney Transplantation;   Focal Segmental Glomerulosclerosis (FSGS)
    Interventions:   Drug: Bleselumab;   Drug: Basiliximab;   Drug: Mycophenolate Mofetil (MMF);   Drug: Tacrolimus Capsules;   Drug: Methylprednisone;   Drug: Prednisone
    Sponsors:   Astellas Pharma Global Development, Inc.;   Kyowa Kirin Co., Ltd.
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Conditions:   Kidney Transplant;   Adult Living Donor Kidney Transplant Recipients;   Renal Transplant;   Living Kidney Donor
    Interventions:   Biological: Polyclonal Regulatory T Cells;   Biological: Donor-Alloantigen-Reactive Regulatory T Cells;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Procedure: Biopsy, Kidney;   Procedure: Blood Draw;   Procedure: Leukapheresis;   Procedure: IS regimen conversion
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Condition:   Kidney Transplant
    Interventions:   Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin®;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
    Interventions:   Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
    Sponsors:   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Los Angeles;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   Baylor College of Medicine;   Children's Hospital of Philadelphia;   Memorial Sloan Kettering Cancer Center;   University of Wisconsin, Madison;   Karolinska University Hospital
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Calciphylaxis
    Interventions:   Drug: Sodium Thiosulfate;   Drug: Placebo-Normal Saline
    Sponsor:   Hope Pharmaceuticals
    Recruiting


PaidClinicalTrials.orgPaidClinicalTrials.org